BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38317348)

  • 1. Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation.
    Keutler A; Lainka E; Posovszky C
    Pediatr Transplant; 2024 Feb; 28(1):e14687. PubMed ID: 38317348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.
    Pittet LF; Verolet CM; McLin VA; Wildhaber BE; Rodriguez M; Cherpillod P; Kaiser L; Siegrist CA; Posfay-Barbe KM
    Am J Transplant; 2019 Mar; 19(3):844-854. PubMed ID: 30171797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
    Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
    Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.
    Feldman AG; Beaty BL; Ferrolino JA; Maron G; Weidner HK; Ali SA; Bitterfeld L; Boulware MA; Campbell KM; Carr E; Chapman S; Chang YC; Cunningham R; Dallas RH; Dantuluri KL; Domenick BN; Ebel NH; Elisofon S; Fawaz R; Foca M; Gans HA; Gopalareddy VV; Gu C; Gupta NA; Harmann K; Hollenbeck J; Huppler AR; Jaramillo C; Kasi N; Kerkar N; Lerret S; Lobritto SJ; Lopez MJ; Marini E; Mavis A; Mehra S; Moats L; Mohandas S; Munoz FM; Mysore KR; Onsan C; Ovchinsky N; Perkins K; Postma S; Pratscher L; Rand EB; Rowe RK; Schultz D; Sear K; Sell ML; Sharma T; Stoll J; Vang M; Villarin D; Weaver C; Wood P; Woodford-Berry O; Yanni G; Danziger-Isakov LA
    JAMA Netw Open; 2023 Oct; 6(10):e2337602. PubMed ID: 37824141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
    Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
    Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.
    Kamei K; Miyairi I; Ishikura K; Ogura M; Shoji K; Funaki T; Ito R; Arai K; Abe J; Kawai T; Onodera M; Ito S
    J Pediatr; 2018 May; 196():217-222.e1. PubMed ID: 29499990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Hamad Saied M; van Straalen JW; de Roock S; de Joode-Smink GCJ; Verduyn Lunel FM; Swart JF; Wulffraat NM; Jansen MHA
    Vaccine; 2023 Aug; 41(37):5477-5482. PubMed ID: 37516575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
    Gothefors L; Bergström E; Backman M
    Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.
    La Torre G; Saulle R; Unim B; Meggiolaro A; Barbato A; Mannocci A; Spadea A
    Hum Vaccin Immunother; 2017 Aug; 13(8):1879-1883. PubMed ID: 28604255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.